Skip to Main Content

574

Views

0

CrossRef citations to date

0

Altmetric

Original Article

Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis

James J. Wua Kite, A Gilead Company, Santa Monica, CA, USACorrespondence[email protected]

https://orcid.org/0000-0003-4130-4601 View further author information

,

Sally W. Wadeb Wade Outcomes Research & Consulting, Salt Lake City, UT, USAView further author information

,

Taha Itanic Kite, A Gilead Company, Munich, GermanyView further author information

,

Jean-Gabriel Castaigned Kite, A Gilead Company, Paris, FranceView further author information

,

Ioana Kloosd Kite, A Gilead Company, Paris, FranceView further author information

,

Weimin Penga Kite, A Gilead Company, Santa Monica, CA, USAView further author information

,

Steve Kanterse RainCity Analytics, Vancouver, Canada

https://orcid.org/0000-0003-0322-5398 View further author information

,

Michael J. Zorattie RainCity Analytics, Vancouver, Canada

https://orcid.org/0000-0003-3069-1159 View further author information

,

Martin Dreylingf LMU University Hospital of Munich, Munich, GermanyView further author information

,

Bijal Shahg Moffitt Cancer Center, Tampa, FL, USAView further author information

&

Michael Wangh The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information